Default DAPT Duration ≥ 12 Months Post ACS Strategy Tool
Patient assessment
Review the factors that influence whether a 12-month dual antiplatelet therapy strategy is appropriate.
Clinical context
Dual antiplatelet therapy (DAPT), typically aspirin plus an oral P2Y12 inhibitor, reduces recurrent atherothrombotic events after acute coronary syndrome (ACS), but increases bleeding. For many ACS patients who are not at high bleeding risk and do not require long-term oral anticoagulation, 12 months of DAPT is the default strategy.
The default duration is not a one-size-fits-all prescription. Bleeding risk, recurrent ischemia, the ACS treatment pathway, procedural details, comorbidities, contraindications, adherence, and patient preferences should be reviewed. For ACS patients who require long-term oral anticoagulation after PCI, the 2025 ACC/AHA guideline recommends discontinuing aspirin after 1 to 4 weeks of triple therapy and continuing an oral anticoagulant plus a P2Y12 inhibitor, preferably clopidogrel. Timing and regimen must be individualized to the clinical setting and bleeding or ischemic risk.
This tool summarizes selected decision factors; it does not calculate a validated risk score and does not replace a complete clinical assessment.
Reference
Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology. 2025. doi:10.1016/j.jacc.2024.11.009.
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.